Please assess the completion status of the following clinical trial:

Trial Title: CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed, informed consent~2. Age 18 or older (for all treatment locations with exception of Taiwan), or age 20 or older (Taiwan only)~3. Pathologically or cytologically-confirmed, advanced-stage hepatocellular carcinoma without prior systemic treatment except for prior immunotherapy and Child-Pugh liver function class A appropriate for treatment with sorafenib~4. Measurable disease according to modified Response Evaluation Criteria in Solid Tumors criteria (mRECIST)~5. Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 1~6. Adequate laboratory parameters including:~   1. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN), or AST and ALT ≤ 5.0 x ULN if liver function abnormalities are due to underlying malignancy~  2. Total serum bilirubin ≤ 2.0 x ULN (except for subjects with documented Gilbert's syndrome who have a limit of ≤ 3.0 x ULN)~  3. Absolute neutrophil count (ANC):1500/µL~  4. Platelets: 90,000/µL~  5. Hemoglobin: 9.0 g/dL~  6. Serum creatinine ≤ 2.0 x ULN or creatinine clearance of ≥ 50 mL/min~  7. Serum albumin ≥ 3.0 g/dL~  8. International normalized ratio (INR) ≤ 1.4~  9. Prothrombin Time (PT)/ Activated Partial Thromboplastin Time (aPTT) ≤ 1.2 x ULN~7. QTc interval (using Fridericia correction) of ≤ 470 msec (QTc interval may be derived from up to 3 separate EKGs performed at least 5 minutes apart)~8. Willingness to participate in collection of pharmacokinetic and other exploratory blood collection as defined in the protocol~9. Willingness to use adequate contraception throughout study and for a period of 3 months after last dose of CVM-1118~Exclusion Criteria:~1. Major surgery (other than diagnostic surgery) or radiation therapy within 28 days of starting study treatment~2. Prior systemic immunotherapy for hepatoma within 28 days of starting study treatment~3. Systemic anticancer therapy (e.g., chemotherapy, hormonal, investigational, biological therapies) within 28 days (or fewer than 5 half-lives, whichever is shorter) of starting study treatment except for ongoing hormonal therapy administered for control of a second cancer (e.g., breast or prostate cancer)~4. Receipt of a CYP3A4 inducer less than 28 days or 5 half-lives of the CYP3A4 inducer prior to the first day of sorafenib administration~5. Other known active cancer(s) likely to require treatment in the next two (2) years or likely to impact the assessment of any study endpoints~6. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy (e.g., subjects with known HBV or HCV infections controlled on antivirals are allowed)~7. Known Central Nervous system (CNS) metastases unless appropriately treated and neurologically stable for ≥ 4 weeks off steroids~8. Pregnant or currently breast-feeding~9. Known HIV-positive~10. Patients with impaired gastrointestinal (GI) diseases that may significantly alter the absorption of oral medications~11. Psychiatric illness/social situations that would interfere with compliance with study requirements~12. History of clinically significant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure (New York Heart Association classification ≥ 2), unstable angina, poorly controlled arrhythmias, myocardial infarction within 6 months of study entry~13. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that would impart, in the judgement of the PI and/or Sponsor, excess risk associated with study participation or study drug administration, which would make the subject inappropriate for entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib + CVM-1118 (Type: EXPERIMENTAL): Cycle 0 (at least 3 weeks): sorafenib tolerability assessment period (sorafenib alone)~400mg BID daily (starting dose); The subject will be assessed for the need for a dose reduction in sorafenib during this period.~Cycle 1+ (28-day cycles): combination period (sorafenib+CVM-1118)~Tolerable dose of sorafenib and CVM-1118 150 (starting dose) or 200 mg BID will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal.

Based on this trial design, predict the completion outcome and termination type (if applicable).